Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

2024-12-05
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options

2024-12-04
Investors need to pay close attention to Amphastar Pharmceuticals (AMPH) stock based on the movements in the options market lately.

Why Amphastar Pharmaceuticals (AMPH) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

2024-11-30
We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against the other most profitable pharmaceutical stocks. The Pharmaceutical Industry: Growth, Innovation, and Emerging Challenges Healthcare, which includes numerous businesses that offer patient care, conduct […]

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

2024-11-26
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the ...

General Motors: A Top Pick On The Quant Dean's List

2024-11-25
My Dean’s List is a small group of companies earning top grades across all five of Seeking Alpha's Quant factors. Read why GM stock is the group's top pick for 2025.

Amphastar initiated with an Equal Weight at Wells Fargo

2024-11-23
Wells Fargo initiated coverage of Amphastar (AMPH) with an Equal Weight rating and $55 price target The firm likes the setup heading into 2025, saying Amphastar could have 2-3 new launches over the next 12 months, “yet is trading as if there is no pipeline.” Amphastar has a solid commercial business and just a few pipeline wins could drive long-term growth, the analyst tells investors in a research note. Wells sees 20% upside in the shares as the company enters a new product cycle. Published fir

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

2024-11-14
RANCHO CUCAMONGA - Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside...

Amphastar Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

2024-11-08
Amphastar Pharmaceuticals ( NASDAQ:AMPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$191.2m (up 5.9...

Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call

2024-11-07
Q3 2024 Amphastar Pharmaceuticals Inc Earnings Call

Amphastar Pharmaceuticals : Quarterly Report for Quarter Ending 2024 09 30 (Form 10 Q)

2024-11-07
Table of Contents ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION ...